Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
AssigneeImmunomedics, Inc.
InventorsDavid M. Goldenberg, William A. Wegener
Life of this patent
Estimating the term…
Abstract
The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.
Claims41
A method of treating hematologic cancer comprising administering a dosage of anti-HLA-DR antibody or antigen-binding fragment thereof to a human patient with a hematologic cancer by parenteral injection.
A method of treating an autoimmune or immune dysfunction disease comprising administering a dosage of anti-HLA-DR antibody or antigen-binding fragment thereof to a human patient with an autoimmune disease by subcutaneous injection.
Dependencies are inferred from the claim text.